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Is Varicella-Zoster Virus Involved in the Etiopathogeny of
Pityriasis Lichenoides?
To the Editor:
Pityriasis lichenoides (PL), previously known as parapsoriasis
guttata, is a squamous cutaneous disease observed mostly in chil-
dren and young adults (Gelmetti et al, 1990). Most cases are char-
acterized by an acute phase and a prolonged course lasting several
months or years. Two major clinical forms may be distinguished:
pityriasis lichenoides chronica and pityriasis lichenoides et vario-
liformis acuta. According to clinicopathologic features, however,
they are considered as part of a spectrum rather than as single
entities.
Although some etiologic investigations have been performed
in this disease, its cause remains unknown. Nevertheless, some
epidemiologic and clinical features suggest that infectious diseases
could trigger PL. Moreover, the recently reported occurrence of
PL just after chicken pox (Stephan et al, 2001) suggests a potential
role of varicella-zoster virus (VZV) in the etiopathogenesis of PL.
To test this hypothesis, we carried out a prospective clinical and
molecular study on skin samples from 13 cases of PL and 22 con-
trol subjects, looking for VZV genomic sequences after gaining
approval from our Institutional Review Board.
All patients with a suspected diagnosis of PL seen in our out-
patient department from January 2001 to January 2002 were en-
rolled. During this period, a group of patients who underwent
skin biopsy or excision for a benign tumor or non-PL in£amma-
tory skin disease served as controls. History related to PL and
chicken pox was obtained, and skin biopsies (for histologic exam-
ination and molecular analyses) and blood samples were taken.
DNA was extracted from fresh biopsies from both groups, fol-
lowed by a blind polymerase chain reaction (PCR) analysis to
amplify genomic sequences of VZV, herpes simplex virus, and
human herpesvirus 6 (and b-globin in cases of negative results).
Positive and negative controls were used for each PCR analysis.
A pair of primers (VZ 7 andVZ 8) was used to detect VZV DNA
sequences hybridized to the XbaI M region, which does not con-
tain sequence homologies with other herpesviruses (Puchham-
mer-St˛ckl et al, 1991). VZV serologic determinations were also
performed (Enzygnost VZV IgM and IgG; Behring, Marburg,
Germany). Then, all patients were invited to participate in an
open trial to assess the bene¢cial therapeutic e¡ects of aciclovir
(given before age 10) or valaciclovir (after age 10). After a 2 wk
treatment, improvement was self-evaluated by the patients (or
their parents) and by a dermatologist, and classi¢ed into four
groups: no change, slight improvement (o 50%), clear improve-
ment (450%), and complete remission.
Thirteen patients with PL were enrolled and there were 22
control subjects. There was no seasonal in£uence on the recruit-
ment of patients and controls.The diagnosis of PLwas con¢rmed
by comparing clinical and histologic criteria. The mean delay be-
fore referral was 6 mo (7 d to 30 mo). In the patient group, all
cases except one had a medical history suggestive of chicken
pox, and 19 of 22 in the control group. By using PCR, genomic
sequences of VZV were found in skin samples from eight cases
(61.5%) and never in control subjects (po0.0001) (Table I). The
mean age of the patients that had a positive result forVZVwas 16 y
(range 2.5^40), and 7.9 y (range 3.5^14) in the negative PCR
group. Moreover, the VZV-negative patients group had a
shorter clinical course than the VZV-positive patients (1.26
mo vs 12.4 mo). In accordance with anamnestic data, anti-
bodies against VZV were found in all PL patients with a clinical
history of chicken pox. The results of the therapeutic trial
carried out in 12 of the 13 cases showed a signi¢cant improve-
ment of the cutaneous lesions in eight cases (complete remission
in two of them), a slight improvement in two cases and no
change in two cases (Table I). Clinical presentation, extent, or
duration of the disease did not correlate with the presence of
VZV in skin samples. Furthermore, no correlations were
found between VZV-positive patients and response to anti-virus
therapy.
Several epidemiologic and clinical features suggest that infec-
tious diseases could trigger PL, i.e., young age at onset, acute
eruptive phase, familial cases (with improvement observed after
treatment with topical aciclovir and betamethasone in a ¢ve-
member family), and a low ratio of circulating T4-positive to
T8-positive cells as observed in viral diseases (Dupont, 1995).
Moreover, the clinical similarity with chicken pox as well as cases
following chicken pox point to the involvement of the VZV.We
found VZV genomic sequences in skin from patients, suggesting
that PL could be triggered by a form of VZVreactivation recently
reported in cases of VZV-induced chronic lichenoid dermatoses
and chronic hyperkeratotic lesions (Nikkels et al, 1997). In those
cases,VZV infection was characterized by a chronic, noncytolytic,
low productive infection of keratinocytes, which was explained
by a reduced late gene expression (Nikkels et al, 1997). In this
study, the VZV-positive patients were older than the VZV-nega-
tive ones and have had chicken-pox for a long time. This does
not support the hypothesis of a persistent presence of VZV
DNA following chicken-pox.
The absence of detection of VZVgenomic sequences in ¢ve of
13 cases suggests that other etiologic factors exist, as is the case in
several prolonged skin reactions, such as childhood papular acro-
dermatitis. On the other hand, a low VZV load leading to false-
negative results cannot be ruled out.
A multicentric prospective study is now required to con¢rm
these results, including a randomized therapeutic trial to assess
the e⁄cacy of aciclovir or valaciclovir on PL.
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Table I. Summary of clinical and laboratory data
Sex Age (y) Type of PL Clinical course VZV PCR HHV6 PCR HSV1 PCR HSV2 PCR b-globin PCR Response to treatment
PL patients M 2.5 PLEVA 1 + ^ ^ ^ ND ND
F 14 PLC 36 + ^ ^ ^ ND ++
M 25 PLC 3 + ^ ^ ^ ND 0
F 40 PLC 14 + ^ ^ ^ ND ++
F 22 PLC 9 + ^ ^ ^ ND +
M 14 PLC 1 + ^ ^ ^ ND +++
F 11 PLC 5 + ^ ^ ^ ND +
F 5 PLEVA 30 + ^ ^ ^ ND ++
F 6.5 PLC 1.5 ^ ^ ^ ^ + +++
M 14 PLEVA 0.5 ^ ^ ^ ^ + ++
M 12 PLEVA 0.5 ^ ^ ^ ^ + ++
M 3 PLC 1 ^ ^ ^ + 0
F 3 PLC 4 ^ ^ ^ ^ + ++
Total PL patients 6 F 11.3 ^ 8 8þ n 0 0 0 NA
7 M (2^40) 61.5%
Controls n¼ 22 11F 11.6 ^ ^ 0n ^ ^ ^ 100% NA
11M (4^49) (0%)
Clinical improvement: 0, no change; +, improvemento50%; ++, improvement450%; +++, complete remission. npo0.0001 (w2 test).
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